Galip Can Uyar/LinkedIn
Jun 25, 2025, 05:45
Galip Can Uyar: Female Patients Showed Better Outcomes with Atezolizumab/Bevacizumab
Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared on X about a recent paper by Federica Lo Prinzi et al. published in Springer Nature:
“A real-world comparative effectiveness study of Atezolizumab + Bevacizumab vs. Tremelimumab + Durvalumab (STRIDE) in advanced hepatocellular carcinoma (HCC).
No significant OS difference overall
Female patients showed better outcomes with Atezo/Beva (HR 1.77, p=0.04)Insightful data from >2,300 patients using the TriNetX network.
A must-read for HCC treatment decision-making.”
Title: Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
Authors: Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Camera, Silvia Foti, Mara Persano, Francesco Vitiello, Emanuela Di Giacomo, Mariam Grazia Polito, Margherita Rimini and Andrea Casadei-Gardini
Other posts featuring Galip Can Uyar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 05:40
Jun 24, 2025, 15:53